عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

National Center for Wildlife Releases 85 Wild Animals into Royal Reserve of Prince Mohammed bin Salman

The release program primarily focuses on reintroducing endangered indigenous species to their natural habitats. (SPA)
The release program primarily focuses on reintroducing endangered indigenous species to their natural habitats. (SPA)
TT
TT

National Center for Wildlife Releases 85 Wild Animals into Royal Reserve of Prince Mohammed bin Salman

The release program primarily focuses on reintroducing endangered indigenous species to their natural habitats. (SPA)
The release program primarily focuses on reintroducing endangered indigenous species to their natural habitats. (SPA)

The National Center for Wildlife, in cooperation with the Prince Mohammed bin Salman Royal Reserve, on Sunday released 85 endangered animals, the first batch in the 2023-2024 season, SPA said.
The release is part of the center's program concerned with increasing and relocating endangered wild animals, restructuring ecosystems, and enriching the biodiversity in the Kingdom of Saudi Arabia.
The animals released this morning are 20 Arabian oryx, 40 rim antelopes, six mountain gazelles, six alpine ibexes, and a number of birds rehabilitated in the shelter unit, comprising: four steppe eagles, four griffon vultures, one lappet-faced vulture, and four pharaoh eagle-owls.
The release was made possible by the many cooperation programs between the reserve and the center to rehabilitate the reserve's ecosystems, enrich biodiversity and achieve national targets.
National Center for Wildlife CEO Dr. Muhammed Qurban said the release program aims mainly at returning endangered indigenous species to their natural habitats.
This is one of the programs of the Saudi Green Initiative, carried out in the implementation of the National Environment Strategy in order to achieve sustainable development, wildlife growth and biodiversity, in line with global environmental conservation efforts.
It is also a step that underlines the depth of cooperation between the center and national stakeholders with mutual interest.
Qurban added that the center owns facilities specializing in the reproduction and localization of endangered organisms in their natural habitats, as per the most accurate global standards; it carries out research on their living conditions, follows up and monitors biodiversity in protected areas using modern techniques to track wildlife group, collects data and understands the risks incurred by wildlife.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”